Whitener Capital Management Inc. Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Whitener Capital Management Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 7.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,958 shares of the company’s stock after selling 1,618 shares during the quarter. Johnson & Johnson makes up approximately 0.8% of Whitener Capital Management Inc.’s holdings, making the stock its 28th biggest position. Whitener Capital Management Inc.’s holdings in Johnson & Johnson were worth $2,886,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its position in shares of Johnson & Johnson by 15.3% during the 2nd quarter. Pacer Advisors Inc. now owns 240,605 shares of the company’s stock valued at $35,167,000 after acquiring an additional 31,908 shares during the last quarter. Sei Investments Co. raised its stake in Johnson & Johnson by 10.7% during the second quarter. Sei Investments Co. now owns 1,126,658 shares of the company’s stock valued at $164,672,000 after purchasing an additional 109,205 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Johnson & Johnson by 31.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company’s stock worth $238,951,000 after buying an additional 394,518 shares in the last quarter. Kiely Wealth Advisory Group Inc. increased its holdings in shares of Johnson & Johnson by 5.7% in the 2nd quarter. Kiely Wealth Advisory Group Inc. now owns 1,847 shares of the company’s stock worth $296,000 after buying an additional 99 shares during the last quarter. Finally, Summit Trail Advisors LLC raised its position in shares of Johnson & Johnson by 30.7% during the 2nd quarter. Summit Trail Advisors LLC now owns 45,920 shares of the company’s stock valued at $6,712,000 after buying an additional 10,789 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. Guggenheim upped their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada boosted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $174.29.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 0.5 %

Shares of Johnson & Johnson stock opened at $147.03 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a market cap of $353.99 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. The firm’s 50-day moving average is $148.51 and its two-hundred day moving average is $155.96.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.